TL;DR
Listen free for 30 days with Audible
Thousands of audiobooks and originals — cancel anytime.
Start your free trialAs an affiliate, we earn on qualifying purchases.
Insilico Medicine has named ISM9077 as a preclinical candidate targeting Y protein, marking a significant step in AI-driven drug development. The candidate shows promise for ocular, inflammatory, and aging disorders.
Insilico Medicine has officially nominated ISM9077 as a preclinical candidate, positioning it as a potential first-in-class drug targeting Y protein for ocular diseases, inflammatory disorders, and aging-related conditions. This development signifies a key milestone in their AI-driven drug discovery platform, highlighting the company’s progress in translating computational predictions into tangible drug candidates.
The nomination was announced via a press release from PR Newswire on March 2024. ISM9077 is described as an AI-empowered pipeline-in-a-drug candidate targeting the Y protein, which is implicated in multiple disease pathways. Insilico Medicine states that ISM9077 has demonstrated promising preclinical activity, supporting its progression toward further testing. The company emphasizes that this candidate could be the first in a new class of drugs, leveraging advanced AI algorithms to accelerate discovery and development processes. Details on the specific preclinical data or efficacy metrics have not been publicly disclosed, but the announcement underscores the company’s confidence in the candidate’s potential.Implications of AI-Driven Drug Discovery Milestone
This announcement underscores the growing role of artificial intelligence in drug discovery, particularly in identifying novel targets and candidates more efficiently than traditional methods. If successful, ISM9077 could pave the way for new treatments in ocular diseases, inflammatory conditions, and aging-related disorders. The nomination also signals Insilico Medicine’s intent to accelerate its pipeline, potentially reducing the time and cost associated with bringing new drugs to market. For investors and industry observers, this development highlights the increasing viability of AI-powered platforms to generate clinically relevant candidates, potentially transforming pharmaceutical R&D.
Eyes Optifusion Drops, Nano Drop Gentle Daily Solution，Contains lutein and vitamins. 2pcs
- Product Type: Eyes Optifusion Drops
- Quantity: 2 pieces
- Main Ingredients: Lutein and vitamins
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background on Insilico’s AI-Driven Approach
Insilico Medicine has been a pioneer in applying AI and machine learning to drug discovery since its founding. The company’s platform integrates large datasets, predictive modeling, and generative algorithms to identify novel drug targets and candidates rapidly. In recent years, Insilico has announced several collaborations and milestones, including the discovery of compounds for cancer and fibrosis. The nomination of ISM9077 as a preclinical candidate represents a significant step in validating the practical application of its AI pipeline in advancing drugs toward clinical development. Prior to this, the company has disclosed promising preclinical results for other candidates, but none have yet reached this stage of formal nomination.
“The nomination of ISM9077 as a preclinical candidate demonstrates the power of our AI platform to identify and advance promising drug candidates rapidly. We believe this candidate has the potential to become a first-in-class therapy for multiple indications.”
— Alex Zhavoronkov, CEO of Insilico Medicine
Turmeric Curcumin Supplement – 95% Curcuminoids with Organic Turmeric & Ginger, BioPerine Black Pepper Extract for Best Absorption, Natural Vegan Joint Support, Non-GMO, Bottled in USA – 60 Capsules
- High Potency Curcuminoids: 95% standardized curcuminoids, 1800mg per serving
- Organic Turmeric & Ginger: Contains organic turmeric and ginger for joint support
- Enhanced Absorption: Fortified with BioPerine black pepper extract
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unconfirmed Data and Next Development Steps
Details regarding the specific preclinical efficacy data, safety profiles, or biomarkers for ISM9077 have not been publicly disclosed, leaving some uncertainty about its readiness for clinical trials. It is also unclear when the candidate will enter the IND-enabling studies or clinical phases. The company has not announced timelines or specific milestones beyond the nomination itself, and independent validation of the preclinical results remains pending.
Cata-Kor NMN Supplement – 4-in-1 NAD Supplement with Quercetin | TMG | Resveratrol – NMNH Alternative – Supports Cellular Energy & NAD+ Level – 60 Capsules – Third-Party Tested (1 Pack)
- Supports NAD+ Levels: Boosts cellular energy and mitochondrial health
- Science-Driven Formula: Includes Quercetin, Resveratrol, and TMG
- Third-Party Tested: Ensures safety and quality in the USA
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Upcoming Milestones for ISM9077 Development
Insilico Medicine is expected to initiate further preclinical studies to validate ISM9077’s safety and efficacy. The company may also seek regulatory feedback to plan for Investigational New Drug (IND) application submission. Monitoring for updates on the progression of ISM9077 into clinical trials will be crucial, alongside potential announcements of additional candidates from the same platform. Industry analysts will be watching whether the candidate’s preclinical promise translates into clinical success.
Applied Artificial Intelligence for Drug Discovery: From Data-Driven Insights to Therapeutic Innovation
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is ISM9077?
ISM9077 is a drug candidate identified by Insilico Medicine’s AI platform, targeting the Y protein for potential treatment of ocular, inflammatory, and aging-related diseases.
Why is this development significant?
This marks a major milestone in AI-driven drug discovery, demonstrating the potential to rapidly identify and advance novel drug candidates with promising therapeutic applications.
When will ISM9077 enter clinical trials?
Insilico Medicine has not yet announced specific timelines. The next steps involve further preclinical validation before regulatory submission for clinical trial approval.
What diseases could ISM9077 target?
The company indicates potential applications in ocular diseases, inflammatory disorders, and age-related conditions, but specific indications will depend on ongoing preclinical results.
How does AI improve drug discovery?
AI accelerates the identification of promising targets and compounds by analyzing large datasets and predicting biological activity, reducing the time and cost of traditional methods.
Source: primary
Baby shower & registry season Picks
baby registry must-haves
As an affiliate, we earn on qualifying purchases.
